The Rheumatologist
COVID-19 News
  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed
  • Home
  • Conditions
    • Rheumatoid Arthritis
    • SLE (Lupus)
    • Crystal Arthritis
      • Gout Resource Center
    • Spondyloarthritis
    • Osteoarthritis
    • Soft Tissue Pain
    • Scleroderma
    • Vasculitis
    • Systemic Inflammatory Syndromes
    • Guidelines
  • Resource Centers
    • Ankylosing Spondylitis Resource Center
    • Gout Resource Center
    • Rheumatoid Arthritis Resource Center
    • Systemic Lupus Erythematosus Resource Center
  • Drug Updates
    • Biologics & Biosimilars
    • DMARDs & Immunosuppressives
    • Topical Drugs
    • Analgesics
    • Safety
    • Pharma Co. News
  • Professional Topics
    • Ethics
    • Legal
    • Legislation & Advocacy
    • Career Development
      • Certification
      • Education & Training
    • Awards
    • Profiles
    • President’s Perspective
    • Rheuminations
  • Practice Management
    • Billing/Coding
    • Quality Assurance/Improvement
    • Workforce
    • Facility
    • Patient Perspective
    • Electronic Health Records
    • Apps
    • Information Technology
    • From the College
    • Multimedia
      • Audio
      • Video
  • Resources
    • Issue Archives
    • ACR Convergence
      • Systemic Lupus Erythematosus Resource Center
      • Rheumatoid Arthritis Resource Center
      • Gout Resource Center
      • Abstracts
      • Meeting Reports
      • ACR Convergence Home
    • American College of Rheumatology
    • ACR ExamRheum
    • Research Reviews
    • ACR Journals
      • Arthritis & Rheumatology
      • Arthritis Care & Research
      • ACR Open Rheumatology
    • Rheumatology Image Library
    • Treatment Guidelines
    • Rheumatology Research Foundation
    • Events
  • About Us
    • Mission/Vision
    • Meet the Authors
    • Meet the Editors
    • Contribute to The Rheumatologist
    • Subscription
    • Contact
  • Advertise
  • Search
You are here: Home / Articles / How to Manage, Treat Anemia of Inflammation in Patients with Rheumatic Disease

How to Manage, Treat Anemia of Inflammation in Patients with Rheumatic Disease

December 17, 2017 • By Ruth Jessen Hickman, MD

  • Tweet
  • Email
Print-Friendly Version / Save PDF

Some patients without clear-cut iron-deficiency anemia seem to benefit from iron-replacement therapy, although this may partially represent a degree of undiagnosed iron deficiency. However, caution should be used in giving extended iron treatments in patients who do not have an underlying iron deficiency, because this may actually aggravate underlying rheumatic disease. Iron overload is also a risk for patients receiving repeated iron therapy.8

You Might Also Like
  • How to Manage Patients with Giant Cell Arteritis and Polymyalgia Rheumatica
  • Plasma Complement Activation in Rheumatic Diseases May Accelerate Coronary Artery Disease
  • Pediatric Rheumatology Research Highlights Successful Approaches to Manage Juvenile Rheumatic Diseases
Explore This Issue
December 2017
Also By This Author
  • Rheumatologists Find Nailfold Capillaroscopy an Increasingly Useful Diagnostic Tool

Erythropoietin-Stimulating Agents, Blood Transfusions & Target Hemoglobin

Erythropoietin-stimulating agents may be helpful in some patients with anemia of inflammation. Patients may also benefit if they have both anemia of inflammation and true iron deficiency but fail to respond to iron therapy. Erythropoietin-stimulating agents have been shown to improve anemia in patients with systemic inflammatory diseases, but response rates vary based on disease type, activity, iron availability and other factors. Use of erythropoietin-stimulating agents has been associated with gains in quality of life and reduced blood transfusions. However, treatment can result in iron deficiency due to increasing demands of iron for red blood cell production.1

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

Dr. Koury explains some other concerns with the use of these agents. “The degree of anemia with chronic disease is not usually that severe, and whenever you give [erythropoietin] to patients, you should be aware of the possibility of thromboses. When a patient is receiving EPO and producing red cells at an increased level, the retic[ulocyte] count can become high relative to the degree of anemia. There may be occasions for EPO administration, but it should be specific to the individual patient.”

Blood transfusions can be used to rapidly treat patients with life-threatening anemia. However, concerns about long-term safety of blood transfusions make this an option that should be used only when necessary. Dr. Koury notes, “I think it’s pretty clear if you are having angina or TIAs and your hematocrit and hemoglobin are low, you have to treat, but you have to be careful. You don’t want to overshoot those situations, because you could actually precipitate a stroke or a heart attack.”

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

There are no randomized controlled trials on target hemoglobin levels in patients with rheumatic disease. Dr. Weiss notes, “In patients with persistent inflammation, it appears that a hemoglobin of 11–12 is better than a normalization based on data obtained with patients on hemodialysis who also suffer from a chronic inflammatory state.”

New Treatment Options on the Horizon

“New therapeutic strategies are emerging based on our expanding knowledge of the pathophysiology of inflammatory anemia,” notes Dr. Weiss. “Anti-hepcidin strategies, which either block hepcidin formation or neutralize this peptide, have been developed and are currently in phase I–III trials for the treatment of inflammatory anemia in different diseases.” The hope is that compounds targeting hepcidin may provide safer and more effective ways of addressing anemia of inflammation.

Pages: 1 2 3 4 5 6 7 8 | Single Page

Filed Under: Conditions Tagged With: anemia, Cause, Clinical, Diagnosis, inflammation, kidney, macrocytic anemia, Management, outcome, pathophysiology, patient care, Rheumatic Disease, rheumatologist, rheumatology, systemic inflammatory syndrome, Test, Treatment, vitamin deficiencyIssue: December 2017

You Might Also Like:
  • How to Manage Patients with Giant Cell Arteritis and Polymyalgia Rheumatica
  • Plasma Complement Activation in Rheumatic Diseases May Accelerate Coronary Artery Disease
  • Pediatric Rheumatology Research Highlights Successful Approaches to Manage Juvenile Rheumatic Diseases
  • Long-Term Benefits, Risks of Biologic Disease-Modifying Anti-Rheumatic Drugs in Patients with RA

About Ruth Jessen Hickman, MD

Ruth Jessen Hickman, MD, was born and raised in eastern Kentucky, where she first cultivated her love of literature, writing and personal narratives. She attended Kenyon college, where she received a Bachelor of Arts in philosophy, summa cum laude. She worked with individuals with psychiatric conditions and later in a neuroscience lab at the University of Illinois, Chicago, before graduating from Indiana University Medical School in 2011. Instead of pursuing clinical medicine, Ruth opted to build on her strength of clearly explaining medical topics though a career as a freelance medical writer, writing both for lay people and for health professionals. She writes across the biomedical sciences, but holds strong interests in rheumatology, neurology, autoimmune diseases, genetics, and the intersection of broader social, cultural and emotional contexts with biomedical topics. Ruth now lives in Bloomington, Ind., with her husband, son and cat. She can be contacted via her website at ruthjessenhickman.com.

View more by this author»

Rheumatology Research Foundation

The Foundation is the largest private funding source for rheumatology research and training in the U.S.

Learn more »

ACR Convergence

Don’t miss rheumatology’s premier scientific meeting for anyone involved in research or the delivery of rheumatologic care or services.

Visit the ACR Convergence site »

American College of Rheumatology

Visit the official website for the American College of Rheumatology.

Visit the ACR »

The Rheumatologist newsmagazine reports on issues and trends in the management and treatment of rheumatic diseases. The Rheumatologist reaches 11,500 rheumatologists, internists, orthopedic surgeons, nurse practitioners, physician assistants, nurses, and other healthcare professionals who practice, research, or teach in the field of rheumatology.

About Us / Contact Us / Advertise / Privacy Policy / Terms of Use

  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed

Copyright © 2006–2021 American College of Rheumatology. All rights reserved.

ISSN 1931-3268 (print)
ISSN 1931-3209 (online)

loading Cancel
Post was not sent - check your email addresses!
Email check failed, please try again
Sorry, your blog cannot share posts by email.
This site uses cookies: Find out more.